Table 3 Univariate and multivariate analysis of post-failure prognostic factors in the locoregional recurrence group

Sex(Female vs. Male)

0.888(0.642–1.229)

0.474

WHO Histology (I ~ II vs. III)

0.729(0.902–1.614)

0.729

Age, year (××45 vs. ≤45)

1.092(0.841–1.419)

0.508

T stage ^a ( T3-4 vs. T1-2)

1.112(0.722–1.712)

0.629

 N stage ^a ( N2-3 vs. N0-1)

0.861(0.662–1.118)

0.262

Overall stage ^a ( IVa vs. III)

1.611(1.223–2.121)

< 0.001

1.544(1.166–2.044)

0.002

EBV DNA load, copy/ml

(≥ 4000 vs. <4000)

1.085(0.825–1.427)

0.559

IC cycle(> 2 cycle vs. 2cycle)

0.983(0.757–1.277)

0.898

CCD, mg/m ²

0.746

0

Reference

1-200

0.954(0.703–1.293)

0.761

> 200

0.760(0.376–1.537)

0.446

ELRFFS

1.640(1.230–2.185)

0.001

1.833(1.367–2.458)

< 0.001

Post treatment

< 0.001

< 0.001

Supportive treatment

Reference

surgery

0.165(0.095–0.284)

< 0.001

0.144(0.083–0.251)

< 0.001

radiotherapy

0.358(0.223–0.575)

< 0.001

0.360(0.224–0.578)

< 0.001

Chemotherapy

0.555(0.354–0.869)

0.010

0.483(0.306–0.761)

0.002

Comprehensive treatment

0.486(0.115–2.057)

0.327

0.554(0.131–2.348)

0.422

Unknown

0.391(0.053–2.896)

0.358

0.359(0.048–2.668)

0.317